This therapeutic antibody drug development webinar, discusses the idea of limiting the substantial investment of time, money, or resources. If you choose the right analytical tools to help make smarter decisions. We highlight why our Prometheus instrument using nanoDSF technology will help to make quantitative, data-driven solutions to help accelerate the therapeutic antibody drug development. Have a listen if you’re a curious scientist who loves learning about new technologies and how they can help make research more efficient!
Want to see more
biologics content?
See more related content
Powering Precision: How Automated Analytical Devices are Driving Smarter Biomanufacturing
Learn about Prometheus Panta C: A next-generation stability characterization platform that's helping biomanufacturers bring automation into the analytical core of their development and process control
Unfolding insights: How nanoDSF is reshaping biotherapeutics development at Johnson & Johnson Innovative Medicine
Dr. Marius Müller of Johnson & Johnson Innovative Medicine shares insights from questions about the use of nanoDSF™ technology for ID-testing and at several late stages of biotherapeutics development.
NanoTemper Announces Prometheus Panta C: Powering Biopharma Breakthroughs from Preclinical to Commercial Manufacturing
NanoTemper Technologies announces the launch of Prometheus Panta C, a solution designed to meet the evolving needs of biopharmaceutical development—from preclinical phase to commercial manufacturing.
3 trends shaping the future of Biomanufacturing
Expert Marius Müller, PhD, Team Lead at Johnson & Johnson Innovative Medicine, shares insights into three significant trends that have potential to reshape the biopharma and biomanufacturing industry
Marius, a biophysics expert at Johnson & Johnson Innovative Medicine, shares his insights into this rapidly evolving field of biomanufacturing.
Learn how to enhance your lab's efficiency with Prometheus Panta, from using capillary chips for high-throughput sample loading to solutions for seamless integration in automated workflows
31:28Watch this webinar to discover how Dr. Marius Müller from Johnson & Johnson Innovative Medicine, uses nanoDSF, a high-throughput method that assesses protein stability, for drug substance ID testing.
5 biologics conferences you won’t want to miss in 2025
Use this curated list of must-attend 2025 biologics conferences to plan your year. Find out when and where each conference takes place, who will be there, and what you can expect.
26:58Watch this webinar about approaches and insights into bispecific formulation development and screening with Prometheus Panta for thermal and colloidal stability characterization of biotherapeutics.
38:20Conversation: How Aaron Frimel from Thermo Fisher Scientific approaches biologics formulation
Join this conversation to gain insight into how the Analytical and Formulation Sciences team at Thermo Fisher Scientific approaches stability assessment of biologic, and how the Prometheus Panta helps
5 types of formulation excipients and how they impact biologics stability
Each excipient class helps stabilize biologics – from monoclonal antibodies to vaccine antigens – in different ways. Read on to learn more about some of the most important excipients for...
22:59Biologics Formulation: Select optimal buffer conditions with multi-parameter stability characterization from Prometheus Panta
Learn how to identify optimal buffer conditions during pre-formulation, with multi-parameter stability characterization from Prometheus Panta, a tool to collect thermal and colloidal data while saving
How Pierre Fabre Laboratories enhances their antibody developability platform
Learn how Pierre Fabre uses multi-parameter stability measurements of mAb libraries on Prometheus Panta to streamline developability platforms, reducing complexity, cost, and sample consumption.
Why Dr. Elsa Wagner from Pierre Fabre chose Prometheus Panta for mAbs developability assessment
Read why scientist Dr. Elsa Wagner chose the Prometheus Panta instrument with simultaneous measurements of DLS, nanoDSF, SLS and backreflection for developability assessment of their mAbs candidates.
16:24De-risk your antibody characterization workflows with high-quality, multi-parameter stability data from Prometheus Panta
Get developability profiles for monoclonal antibodies with stability data from Prometheus Panta to inform on rational design and selection of therapeutic constructs that will succeed in the clinic.
5 considerations for buffer optimization during biologics pre-formulation
The work of pre-formulations scientists is critical to de-risk the entire development process for biologics. Read on to learn more about what to consider about your buffer components for...
17:08Assess the impact of bioconjugation with multi-parameter stability characterization
Characterize the developability of antibody-drug conjugates: Multi-parameter stability assessment with Prometheus Panta makes it possible to examine multiple aspects of ADC stability in parallel.
Get predictive insight into your ADC’s stability with these 3 experiments
Learn how it’s possible to use the Prometheus Panta to extrapolate how your low concentration sample will behave once it’s scaled up and at higher concentrations used for clinical administration.
19:07How stability prediction experiments give you confidence in your ADCs
For antibody-drug conjugate (ADC) development, scientists rely on stability experiments using fluorescence and light scattering techniques to predict the conjugated molecule's behavior.
0:40What are ADCs and how do they work against cancer?
In this short animated video, learn the basics of how antibody-drug conjugates (ADCs) are engineered and why that makes them such powerful tools to target cancers with precision.